Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biosimilar
Biotech
Shire bails out of Baxalta biosimilars, ends Coherus, Momenta deals
Shire has returned rights to the two biosimilars that Baxalta had in development.
Stacy Lawrence
Sep 27, 2016 10:09am
FDA approves a third biosimilar, with the largest market
Aug 30, 2016 7:38pm
Pfizer returns rights to Pfenex for Lucentis biosimilar
Aug 8, 2016 10:05am
Biosimilars' safety and efficacy comparable to brand-name biologics
Aug 3, 2016 7:58am
Amgen, Allergan clear Phase III with Herceptin biosimilar
Jul 21, 2016 10:37am
Japanese generics giant to take out Sagent for $736M
Jul 11, 2016 10:15am
